Research and Markets (http://www.researchandmarkets.com/research/a67df8/competitor_analysi) has announced the addition of the "Competitor Analysis: EGF-R Agonists and Antagonists" report to their offering.
The present Competitive Intelligence Report about EGF-R agonists and antagonists provides a competitor evaluation in the field of epidermal growth factor receptor (EGF-R; ErbB1) targeting molecules for wound healing or treatment of cancer as of September 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The human epidermal growth factor receptor (HER) family members include EGFR (erbB1), HER2/neu (erbB2), HER3 (erbB3), and HER4 (erbB4) that are structurally related, and all except HER3 contain intracellular tyrosine kinase (tk) domain. All of the HER members, except HER2, bind to extracellular ligands.
EGFR, a valid target in many epithelial malignancies, is a transmembrane protein with an extracellular ligand binding domain joined to an intracellular tyrosine kinase domain. Activation of EGFR induces a cascade of downstream signaling through several pathways, such as mitogenac tivated protein kinase (MAPK) and PI3-kinase / Akt/mTOR, resulting in cellular proliferation, differentiation, survival, motility, adhesion, and repair. EGFR is overexpressed or abnormally activated in several epithelial malignancies. Several antibodies targeting EGF-R and small molecules inhibiting the EGF-R tyrosine kinase have been approved and are used for treatment of colorectal cancer, squamous cell cancer of the head & neck or pancreatic cancer, respectively. EGF-R targeting therapeutics achieved 2008 sales of US$ 3.35 bln.